🇺🇸 FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11897874

Compounds and methods for modulating Interleukin-2-inducible T-cell kinase

Corvus Pharmaceuticals, Inc. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11897875

Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric a

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11897873

Kappa opioid receptor antagonists and products and methods related thereto

BLACKTHORN THERAPEUTICS, INC. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11897879

Heterocyclic compound

Takeda Pharmaceutical Company Limited · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11897933

Anti-KRAS-G12D T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11897932

Receptors for ligand-dependent transcriptional regulation

The Regents of the University of California · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11896643

Fibroblast binding agents and use thereof

Orionis Biosciences, Inc · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11896617

Polynucleotides encoding rituximab-resistant chimeric antigen receptors

Allogene Therapeutics, Inc. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11897845

Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11896558

Use of an RXR agonist and taxanes in treating Her2+ cancers

The Board of Regents of the University of Texas System · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11896417

Time-varying kinetic modeling of high temporal-resolution dynamic pet data for multiparame

The Regents of the University of California · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11897945

Methods of treating allergy using anti-Bet v 1 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11898180

Compositions and methods for amino acid depletion therapy

Avalon Polytom (HK) Limited · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11898207

Methods of isolating neoantigen-specific T cell receptor sequences

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11897969

Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury

The Regents of the University of California · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11898158

Methods and compositions for the treatment of lysosomal storage diseases

Sangamo Therapeutics, Inc. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11896682

Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11898165

Engineered host cells and methods of use thereof

MiNK Therapeutics, Inc. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11896672

Targeted nucleic acid conjugate compositions

ARBUTUS BIOPHARMA CORPORATION · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11898166

In vitro generation of thymic organoid from human pluripotent stem cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11896599

Modified release preparations containing oxcarbazepine and derivatives thereof

Supernus Pharmaceuticals, Inc. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11896623

Visco-supplement compositions, and methods of use thereof

Prime Merger Sub, LLC · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11896580

Composition for improving milk quality and preparation method and application thereof

China Agricultural University · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11896007

Pest control using natural pest control agent blends

TYRATECH, INC. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted